mavaCamten ObservationaL evIdence Global cOnsortium in HCM (COLLIGO-HCM).

The COLLIGO-HCM clinical trial, identified as NCT06372457, is a global observational study that aims to gather data on the treatment of hypertrophic cardiomyopathy (HCM) in real-world clinical practice. The trial will collect information on participant demographics, medical history, diagnostic information, and treatment initiation. The goal is to gain insights into HCM treatment and improve patient outcomes. Another document provides a list of measurements and tests conducted on participants in a clinical trial for the drug mavacamten, which is used to treat HCM. The measurements include various cardiac tests and blood creatine levels. The COLLIGO-HCM study is currently active but not recruiting, and it aims to investigate the real-world effectiveness of mavacamten in treating symptomatic obstructive HCM. The study will use existing medical records and electronic registries from HCM centers worldwide. The estimated completion date is June 15, 2025, and the study is being conducted by Bristol-Myers Squibb. [Extracted from the article]